Literature DB >> 28379518

Response assessment in high-grade glioma: tumor volume as endpoint.

Raymond Huang1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28379518      PMCID： PMC5464429          DOI： 10.1093/neuonc/nox035

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  8 in total

1.  Assessment of intra-observer variability in measurement of high-grade brain tumors.

Authors:  James M Provenzale; Michael C Mancini
Journal:  J Neurooncol       Date:  2012-03-10       Impact factor: 4.130

2.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

3.  Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.

Authors:  Jerrold L Boxerman; Zheng Zhang; Yair Safriel; Mykol Larvie; Bradley S Snyder; Rajan Jain; T Linda Chi; A Gregory Sorensen; Mark R Gilbert; Daniel P Barboriak
Journal:  Neuro Oncol       Date:  2013-06-19       Impact factor: 12.300

4.  Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

Authors:  Walter Taal; Hendrika M Oosterkamp; Annemiek M E Walenkamp; Hendrikus J Dubbink; Laurens V Beerepoot; Monique C J Hanse; Jan Buter; Aafke H Honkoop; Dolf Boerman; Filip Y F de Vos; Winand N M Dinjens; Roelien H Enting; Martin J B Taphoorn; Franchette W P J van den Berkmortel; Rob L H Jansen; Dieta Brandsma; Jacoline E C Bromberg; Irene van Heuvel; René M Vernhout; Bronno van der Holt; Martin J van den Bent
Journal:  Lancet Oncol       Date:  2014-07-15       Impact factor: 41.316

5.  Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma.

Authors:  Martha Nowosielski; Benedikt Wiestler; Georg Goebel; Markus Hutterer; Heinz P Schlemmer; Günther Stockhammer; Wolfgang Wick; Martin Bendszus; Alexander Radbruch
Journal:  Neurology       Date:  2014-04-11       Impact factor: 9.910

6.  Bidimensional measurements in brain tumors: assessment of interobserver variability.

Authors:  James M Provenzale; Claro Ison; David Delong
Journal:  AJR Am J Roentgenol       Date:  2009-12       Impact factor: 3.959

7.  Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.

Authors:  Benjamin M Ellingson; Hyun J Kim; Davis C Woodworth; Whitney B Pope; Jonathan N Cloughesy; Robert J Harris; Albert Lai; Phioanh L Nghiemphu; Timothy F Cloughesy
Journal:  Radiology       Date:  2013-11-27       Impact factor: 11.105

8.  The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.

Authors:  Raymond Y Huang; Rifaquat Rahman; Karla V Ballman; Sara J Felten; S Keith Anderson; Benjamin M Ellingson; Lakshmi Nayak; Eudocia Q Lee; Lauren E Abrey; Evanthia Galanis; David A Reardon; Whitney B Pope; Timothy F Cloughesy; Patrick Y Wen
Journal:  Clin Cancer Res       Date:  2015-10-21       Impact factor: 12.531
  8 in total
  3 in total

1.  Differentiation of residual/recurrent gliomas from postradiation necrosis with arterial spin labeling and diffusion tensor magnetic resonance imaging-derived metrics.

Authors:  Ahmed Abdel Khalek Abdel Razek; Lamiaa El-Serougy; Mohamed Abdelsalam; Gada Gaballa; Mona Talaat
Journal:  Neuroradiology       Date:  2017-12-07       Impact factor: 2.804

2.  Tumor Volume Dynamics as an Early Biomarker for Patient-Specific Evolution of Resistance and Progression in Recurrent High-Grade Glioma.

Authors:  Daniel J Glazar; G Daniel Grass; John A Arrington; Peter A Forsyth; Natarajan Raghunand; Hsiang-Hsuan Michael Yu; Solmaz Sahebjam; Heiko Enderling
Journal:  J Clin Med       Date:  2020-06-27       Impact factor: 4.241

3.  Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors.

Authors:  Jian Peng; Daniel D Kim; Jay B Patel; Xiaowei Zeng; Jiaer Huang; Ken Chang; Xinping Xun; Chen Zhang; John Sollee; Jing Wu; Deepa J Dalal; Xue Feng; Hao Zhou; Chengzhang Zhu; Beiji Zou; Ke Jin; Patrick Y Wen; Jerrold L Boxerman; Katherine E Warren; Tina Y Poussaint; Lisa J States; Jayashree Kalpathy-Cramer; Li Yang; Raymond Y Huang; Harrison X Bai
Journal:  Neuro Oncol       Date:  2022-02-01       Impact factor: 13.029
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.